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Abstract
Background: Protein kinase C (PKC) e, a key signaling transducer implicated in mitogenesis, survival, and cancer
progression, is overexpressed in human primary non-small cell lung cancer (NSCLC). The role of PKCe in lung cancer
metastasis has not yet been established.
Principal Findings: Here we show that RNAi-mediated knockdown of PKCe in H358, H1299, H322, and A549 NSCLC impairs
activation of the small GTPase Rac1 in response to phorbol 12-myristate 13-acetate (PMA), serum, or epidermal growth
factor (EGF). PKCe depletion markedly impaired the ability of NSCLC cells to form membrane ruffles and migrate. Similar
results were observed by pharmacological inhibition of PKCe with eV1-2, a specific PKCe inhibitor. PKCe was also required for
invasiveness of NSCLC cells and modulated the secretion of extracellular matrix proteases and protease inhibitors. Finally,
we found that PKCe-depleted NSCLC cells fail to disseminate to lungs in a mouse model of metastasis.
Conclusions: Our results implicate PKCe as a key mediator of Rac signaling and motility of lung cancer cells, highlighting its
potential as a therapeutic target.
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Introduction
Lung cancer is one of the major causes of cancer-related
mortality, with more than 220,000 cases diagnosed and 157,000
deaths estimated for 2010 [1,2]. The genesis of lung cancer involves
the progressive appearance of genetic and epigenetic alterations
bothinoncogenesandtumor-suppressorgenes,ultimatelyleadingto
deregulated activation of mitogenic and survival signaling pathways.
Common alterations in non-small cell lung cancer (NSCLC), the
most prevalent form of lung cancer, include mutations in K-Ras,
overexpression of epidermal growth factor receptor (EGFR) and
Bcl2, as well as inactivation/down-regulation of p53, Rb, and Pten
tumor suppressor genes [3]. Accumulating evidence indicates that
protein kinase C (PKC) expression and/or activity is considerably
altered in human lung cancer [4], although a causal relationship
with disease progression remains to be established. The PKC family
consists of three classes of serine-threonine kinases with distinct
biochemical and regulatory properties: classical/conventional
(cPKCs a, b,a n dc), novel (nPKCs d, e, g,a n dh), and atypical
(aPKCsf and i). cPKCs and nPKCs are responsiveto phorbol esters
and the second messenger diacylglycerol (DAG), a product of PIP2
breakdown by phospholipase C (PLC) in response to activation of
tyrosine-kinase and G-protein-coupled receptors. PKC isozymes




there is surprisingly limited information regarding the role of
individual PKC isozymes in lung cancer progression compared to
other epithelial cancers such as skin, breast or prostate cancer,
where the involvement of PKCs has been extensively documented
[6]. A few available studies established that PKC isozymes display
unique functional properties in lung cancer cells. Our laboratory
reported that NSCLC cells undergo arrest upon activation of either
PKCa or PKCd. Whereas PKCa induces G2/M arrest and
senescence in NSCLC cells, PKCd induces p21
cip1 in the G1 phase
of the cell cycle [7,8,9]. PKCe, on the other hand, drives G1 to S
progression of the cell cycle and has a pro-survival role in NSCLC
cells,asalsodescribedforothercancercellmodels[10,11,12,13,14].
Remarkably, PKCe is abnormally up-regulated in .90% of
primary human NSCLCs compared to normal lung epithelium,
an effect not observed in small cell lung cancer (SCLC) [10]. It is
noteworthy that PKCe has been implicated in oncogenesis in
variouscancer types. Most notably, ectopicoverexpression of PKCe
in non-transformed cell lines confers growth advantage or can even
lead to malignant transformation [14,15,16].
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cancer cell invasion and metastatic dissemination, the specific roles
of individual PKCs remain only partially understood.
[17,18,19,20,21]. Most notably, phorbol esters promote actin
cytoskeleton reorganization and stimulate cell motility in a number
of cell lines [22,23]. Cell type-specific associations between PKC
signaling and small Rho GTPases family have been reported.
Rac1, a member of the Rho family, has been widely implicated in
cytoskeleton rearrangements and cell migration, and play
important roles in tumorigenesis and metastasis [24]. PKC has
been also implicated in the secretion and expression of basement
membrane remodeling proteins, such as matrix metalloproteinases
(MMPs) and urokinase-type plasminogen activator receptor
(uPAR) [17,18,25]. The relationship between individual PKCs
and cell motility/invasiveness in lung cancer cells remains to be
elucidated.
In this study we focused on PKCe and its potential role in the
control of Rac activation and NSCLC cell motility. By means of
RNAi and pharmacological approaches we established a key role
for PKCe in Rac activation in response to growth factor receptor
stimulation, as well as in migration and invasiveness of NSCLC
cells. Our studies may have significant implications for the
understanding of the molecular mechanisms underlying lung
cancer cell metastasis and hopefully underscore novel therapeutic
opportunities for treatment of the disease.
Materials and Methods
Cell culture
Human NSCLC cell lines (H358, H322, H1299 and A549)
were obtained from ATCC and cultured in RPMI 1640 medium
supplemented with 10% FBS, 2 mM glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin. Immortalized human
bronchioepithelial cells (HBEC) were a kind gift from Dr. Trevor
Penning (University of Pennsylvania) and were cultured on gelatin-
coated plates in KSFM medium supplemented with 0.05 mg/ml
bovine pituitary extract and 5 ng/ml EGF.
Adenoviral infections
Cells were infected with adenoviruses (AdVs) encoding b2-
chimaerin, dominant-negative Rac (N17-Rac1), PKCa, PKCd,
PKCe or LacZ (control) at the indicated multiplicities of infection
(MOIs), as previously reported [9]. Experiments were carried out
24 h later.
RNAi
Two different RNAi sequences were used for each target. For
transient depletion of PKCe we used ON-TARGET Plus RNAi
duplexes purchased from Dharmacon (Catalog # J-004653-06, J-
004653-08). For EGFR depletion we used ON-TARGET plus
SMARTpool (L-003114-00-0005). Silencer Control RNAi #3
(Ambion) was used as control. siRNAs were transfected with
LipofectamineRNAi/MAX (Invitrogen). After 48 h cells were
serum starved for 24 h and used for the indicated experiments. For
stable depletion of PKCe, we used shRNA lentiviral particles from
Sigma (Catalog #SHCLNV-NM_005400, clone ID x-741s1c1
and x-375s1c1). Upon infection, cells were selected for 2 weeks
with puromycin (1–2 mg/ml depending on the cell line), as
previously described [26].
Rac-GTP pull-down assays
Determination of Rac-GTP levels was carried out essentially as
previously described [27]. Briefly, cells growing at low confluency
were serum starved for 24 h and stimulated with PMA, FBS or
EGF at the concentrations indicated. Cells were lysed in pull-down
buffer (20 mM Tris-ClH pH 7.4, 150 mM NaCl, 5 mM MgCl2,
0.5% NP40, 5 mM b-glycerophosphate, 1 mM DTT and protease
inhibitors) containing 15 mg/ml of PBD-GST. Lysates were
cleared by centrifugation (10 min at 4uC, 13,0006g) and
incubated with glutathione-Sepharose beads (GE Healthcare) for
45 min at 4uC. After centrifugation, Rac-GTP bound to the beads
was washed twice with pull-down buffer and run on SDS-PAGE.
Rac1 was detected by Western blot using an anti-Rac1 antibody
(Upstate Biotechnology, 1:1000 dilution).
Cytoskeleton morphology assays
Cytoskeleton morphology was assessed as described previously
[26]. Briefly, cells growing on glass coverslides at low confluency
were serum starved for 24 h and stimulated with PMA or FBS at
the concentrations indicated. Following fixation with 4% formal-
dehyde, F-actin was stained with phalloidin-rhodamine and nuclei
were counter-stained with DAPI. Slides were visualized by
fluorescence microscopy and 5 random fields were scored for
presence/absence of ruffles.
Wound assays
Experiments were carried out in triplicate plates essentially as
previously described [26].Three micrographs were obtained at
time=0 h and 9–24 h later depending on the cell line. Wound
closure measurements were normalized to the maximum initial
scratch area for each well.
Migration in Boyden chambers
Cells were serum starved for 24 h, trypsinized, suspended in
0.1% BSA/RPMI, and seeded (1.5610
4 cells/well) in the upper
compartments of the chemotaxis chamber (NeuroProbe). Polycar-
bonate membranes of 8 mM pore diameter were used to separate
the upper and lower compartments. In the lower chamber, RPMI
medium containing 10% FBS was used. After an incubation of
18 h at 37uC, membranes were recovered and cells on the upper
side (non-migratory) wiped off the surface. Cells on the lower side
of the membrane were fixed and stained with DIFF Quik Stain Set
(Dade Behring). Migratory cells in each well were counted by
contrast microscopy in 5 independent fields.
Invasion assays and determination of proteases
Invasion assays using Matrigel-coated polycarbonate mem-
branes were conducted as previously described [5]. The mRNA
levels of extracellular matrix (ECM) proteases and protease
inhibitors were determined by qPCR as described previously
[28]. Briefly, RNA was isolated with the QIAGEN RNeasy kit,
reverse transcribed, and assayed for simultaneous detection of
ECM-related genes and 2 housekeeping genes by qPCR using
RT2 Profiler PCR Array plates (QIAGEN) and a RT2 SYBR
Green/5-carboxy-X-rhodamine (ROX) qPCR master mix. Data
were normalized using GAPDH and b-actin as housekeeping
genes, and the relative levels of mRNA calculated according to the
DCt method. Genes that displayed .1.5-fold change in expression
as a consequence of PKCe depletion were selected for further
analysis.
For the determination of proteases in conditioned medium
(CM), cells (3610
6) were incubated for 48 h in serum-free medium
and the supernatant concentrated using an Amicon Ultra-4
filtration device with a 30 kDa cut-off (Millipore). The concen-
trated CM was used for detection of proteases with a RayBiotech
antibody array following the manufacturer’s instructions, or for
gelatin zymography, as described previously [16].
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Plates were coated with 500 mg/ml Matrigel, blocked with 0.5%
BSA and cells (3610
4 cells/well in 0.1% BSA/RPMI) were seeded
in triplicate. FBS (10%) was added to stimulate adhesion and after
incubation for 18 h at 37uC unattached cells were washed away
with PBS, fixed in methanol and stained with crystal violet solution
(3.5 mg/ml crystal violet, 19% ethanol, 1% methanol). After
solubilization in 2% SDS, optical density was measured at
570 nm.
Experimental metastasis assays and survival in nude mice
Studies were carried out in strict accordance to the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. Protocols were approved by
the Institutional Animal Care and Use Committee (IACUC) of the
University of Pennsylvania (Protocol number 802268) and The
Wistar Institute (Protocol number 112318). Cells were grown to
80% confluency and suspended in PBS. Male athymic mice (6–8
weeks, Harlan Laboratories) were injected i.v. with 5610
5 cells in
0.1 ml (10 mice/group). After 100 days, mice were sacrificed and
the lungs removed, fixed in 4% formaldehyde/PBS, paraffin
embedded, dissected and stained with hematoxilin/eosin (H&E).
The incidence of metastasis was determined as described [29,30].
To determine the area of metastatic lesions, digital images of 2
sections from the 5 lobules from each lung were processed with
ImagePro 6.2, as described previously [31]. For survival studies,
nude mice (10 mice/group) were injected with 2610
6 cells and the
time of death of each animal was recorded.
Western blots
Western blots and densitometric analyses were carried out as
previously described [9,27]. Bands were visualized by Enhanced
Chemiluminescence (ECL) Western blotting detection system.
Images were captured using a FUJIFILM LAS-3000 system and
the LAS-2000 software.
Statistical analysis
Averages of at least 3 independent experiments were compared
with a t-test using GraphPad Prism 3.0. For metastasis experiments,
thedistributionofeach groupwascomparedagainst the distribution
of the control, using a Mann-Withney non-parametric test. In all
cases, a p,0.05 was considered statistically significant.
Results
PKCe mediates PMA-induced Rac activation and Rac-
mediated responses
To determine if PKCs play a role in the regulation of Rac
activity in NSCLC cells, we first examined the effect of phorbol
12-myristate 13-acetate (PMA) on Rac activation in four different
NSCLC cell lines (A549, H358, H1299, and H322). Cells were
treated with 100 nM PMA for different times (0–30 min) and the
levels of Rac1-GTP (active Rac) assessed using a PBD pull-down
assay. As shown in Fig. 1A, PMA induced a fast activation of Rac1
in all four NSCLC cell lines that begins at 1–2 min and is
sustained for at least 30 min. As PMA can directly activate targets
unrelated to PKC that modulate the activity of small GTPases
(such as chimaerins, MRCK or RasGRPs), we examined the effect
of the pan-PKC inhibitor GF19203X (bisindolmaleimide I) [32].
Rac1 activation by PMA was indeed sensitive to the pan-PKC
inhibitor GF109203X, particularly in A549, H358, and H322
cells, suggesting that the effect of the phorbol ester is mediated
primarily through PKC activation (Fig. 1B).
Rac mediates the reorganization of the actin cytoskeleton into
ruffles and lamellipodia, a critical step for cell motility [33,34].
When A549 cells were treated with PMA, a marked induction of
circular ruffles was observed. This effect was essentially abolished
by GF109203X (Fig. 1C). Similar results were observed in H358,
H1299 and H322 cells (Fig. S1). To determine if PMA activates
NSCLC cell motility we used a wound assay. In comparison to
vehicle treatment, which closed the wound by 50–70% depending
on the NSCLC cell line, full closure of the wound was observed in
response to PMA (Fig. S2). PMA-induced NSCLC cell motility
was markedly reduced by the PKC inhibitor GF109203X (Fig. 1D
and Fig S2). These results argue for the involvement of phorbol
ester/DAG responsive PKCs, namely cPKCs and/or nPKCs, in
Rac activation in NSCLC cells.
NSCLC cells express very high levels of PKCe compared to
normal lung epithelial cells (Fig. S3), as also observed in human
NSCLC specimens [10]. To determine if PKCe is implicated in the
regulation of Rac activation and cell motility in NSCLC cells we
knocked-down PKCe using RNAi. Two different siRNA duplexes
(e1a n de2) were used, which led to .80% depletion in all NSCLC
cell lines used (Fig. 2A). Notably, activation of Rac1 by PMA in
PKCe-depleted NSCLCcellswasmarkedlyreduced relative totheir
corresponding control cells transfected with a non-target RNAi
sequence (Fig. 2B). Moreover, PKCe knock down in A549 reduced
phorbol ester-induced ruffle formation (Fig. 2C and 2D) and wound
closure (Fig. 2E). Similar results were observed in H322 cells (Fig.
S4). Our results clearly establish the involvement of PKCe in PMA-
induced Rac activation and motility in NSCLC cells.
PKCe is required for growth factor-induced Rac activation
and NSCLC cell motility
To assess the involvement of PKCs in Rac activation in NSCLC
cells in response to physiological stimuli, we first examined the
effect of the PKC inhibitor GF109203X on serum responses.
A549, H358 and H322 cells were serum-starved for 24 h and Rac-
GTP levels determined in response to acute stimulation with
serum. Addition of FBS activated Rac1 in all NSCLC cell lines,
and this effect was essentially abolished by GF109203X (Fig. 3A).
The requirement of Rac for NSCLC cell migration was
establishedby means of expressing either the RacGTPase activat-
ing protein (Rac-GAP) b2-chimaerin [35] or a dominant-negative
Rac mutant (N17-Rac1) using adenoviral means. Either b2-
chimaerin or N17-Rac1 impaired NSCLC cell motility. The effect
was proportional to the expression levels achieved by increasing
the multiplicities of infection (MOI) of the corresponding AdVs
(Fig. 3Band 3C).
Next, we wished to examine if PKCe mediates the activation of
Rac1 by serum. As shown in Fig. 3D, depletion of PKCe with
either e1o re2 RNAi duplexes impaired Rac1 activation induced
by FBS in A549 cells. In addition, NSCLC cell migration induced
by serum was essentially abolished when PKCe was knocked-down
(Fig. 3E) without affecting cell viability (Fig. S5). GF109203X also
inhibited cell migration, although prolonged incubation with the
‘‘pan’’ PKC inhibitor, as required in the motility assay, reduced
cell viability (Fig. S5). The involvement of PKCe in NSCLC cell
motility was further confirmed by means of an overexpression
approach. Adenoviral delivery of PKCe to H358 or A549 cells
enhanced cell motility. This effect was not observed upon
overexpression of PKCa or PKCd (Fig. S6). These results clearly
implicate PKCe as a mediator of Rac responses in NSCLC cells.
EGF signals to Rac via a PLCc-PKCe-dependent pathway
EGF and PDGF are potent activators of Rac, and they induce
the formation of circular ruffles in a similar manner than PMA
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growth factors could be mediating NSCLC cell motility induced
by FBS, we used EGFR or PDGFR pharmacological inhibitors.
Rac pull-down assays revealed that the EGFR inhibitor AG1478
greatly reduced FBS-induced Rac1 activation in A549 cells. On
the other hand, the PDGFR inhibitor PRI-4 was ineffective
(Fig. 4A). To confirm the involvement of EGFR we knocked it
down using RNAi duplexes. We found that Rac1 activation in
response to FBS was markedly inhibited in EGFR-depleted A549
cells (Fig. 4B), thus reinforcing the conclusions obtained with the
EGFR inhibitor. Both AG1478 and EGFR RNAi also inhibited
FBS-induced A549 cell motility (Fig. 4C). Furthermore, treatment
of A549 cells with EGF (100 ng/ml, 2 min) caused a ,5-fold
induction in Rac-GTP levels, and this effect was essentially
abolished upon PKCe depletion (Fig. 4D). Likewise, ruffle
formation in response to EGF was inhibited as a consequence of
PKCe depletion (Fig. 4E).
PKCe is a downstream effector of EGFR, and it translocates to
the plasma membrane in response to EGF in a DAG-dependent
manner ([38], and data not shown). As EGFR couples to the
DAG-generating enzyme PLCc in response to stimulation [39],
we reasoned that inhibition of PLC should affect Rac activation by
EGF. A549 cells were treated with the PLC inhibitor U73122 or
its inactive analogue U73343 and stimulated with EGF. U73122
Figure 1. PMA activates Rac responses in NSCLC cells. A. NSCLC cells were serum starved for 24 h and treated with PMA (100 nM) for different
times, and Rac-GTP assays determined using a pull-down assay. A representative experiment is shown. The fold-induction in Rac-GTP levels
normalized to total Rac at time=0, as determined by densitometry, is represented in the bottom graphs. Data are expressed as mean 6 S.D. (n=3). B.
Effect of the pan-PKC inhibitor GF109203X (5 mM, 30 min) on Rac activation by PMA (100 nM, 2 min).The fold-induction in Rac-GTP levels normalized
to total Rac at time=0, as determined by densitometry, is represented in the bottom graphs. Data are expressed as mean 6 S.D. (n=3). *, p,0.05;
***, p,0.001. C. A549 cells were treated with PMA (100 nM, 30 min), fixed, and stained with phalloidin-rhodamine. Top, representative micrographs
are shown (n=3). Bottom, quantification of cells bearing ruffles, expressed as mean 6 S.D. of 3 individual experiments. ***, p,0.001. D.Confluent
monolayers of cells were treated with PMA (100 nM, 30 min) and scraped. Closure of wounds was recorded at 9 h (A549 cells) or 20 h (H358 cells)
post-treatment. Experiments were carried out in triplicate plates. Results are expressed as percentage of the closure induced by PMA, and expressed
as mean 6 S.E.M. (n=3). ***, p,0.001.
doi:10.1371/journal.pone.0031714.g001
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analogue did not. As an additional control we used PMA, which
activates Rac1 regardless of PLC inhibition (Fig. 4F). Altogether,
these results argue for the requirement of a PLCc-dependent
activation of PKCe for the activation of Rac1 by EGF. Thus,
PKCe is a downstream effector of EGFR in NSCLC cells.
Pharmacological inhibition of PKCe affects NSCLC cell
migration
To furtherestablishthe requirement ofPKCe forRac1activation
in NSCLC cells we used eV1-2, a specific inhibitor of PKCe
translocation that has been widely used in cellular and animal
models [40,41,42,43]. A549 and H358 cells were incubated with
either eV1-2 or the control peptide (TAT) and analyzed for changes
in motility. In agreement with results observed using PKCe RNAi,
pharmacological inhibition of PKCe significantly reduced the
migratory ability of NSCLC cells in response to FBS (Fig. 5A and
Fig. S7) without affecting cell viability (Fig. S5). eV1-2 also inhibited
ruffle formation in response to FBS (Fig. 5B). Finally, elevation of
Rac-GTP levels in response to FBS or EGF was diminished by
pharmacological inhibition of PKCe (Fig. 5C).
PKCe is implicated in invasiveness and metastasis of
NSCLC cells
The ability of cancer cells to invade and metastasize is
associated with the production and release of proteases that
Figure 2. PKCe mediates Rac activation and Rac-mediated responses induced by PMA. A. NSCLC cells were transfected with either PKCe
RNAi (e1o re2) or control (CTRL) RNAi and serum starved for 24 h. A representative Western blot for PKCe expression at the time of PMA treatment is
shown (n=3). B. Cells subject to PKCe or control RNAi were stimulated with PMA (100 nM, 2 min) and Rac-GTP levels determined using a pull-down
assay.A representative experiment is shown. The fold-induction in Rac-GTP levels normalized to total Rac at time=0, as determined by densitometry,
is represented in the bottom graphs. Data are expressed as mean 6 S.D. (n=3). *, p,0.05; ***, p,0.001. C. A549 cells were treated with PMA
(100 nM, 30 min), fixed, and stained with phalloidin-rhodamine. Representative micrographs are shown (n=3). D. Quantification of A549 cells bearing
ruffles, expressed as mean 6 S.D. of 3 individual experiments. **, p,0.01; ***, p,0.001. E. Closure of wounds in response to PMA (100 nM, 30 min)
was recorded at 9 h (A549 cells). Experiments were carried out in triplicate plates. Results are expressed as percentage of the closure induced by PMA,
and expressed as mean 6 S.E.M. (n=3). ***, p,0.001.
doi:10.1371/journal.pone.0031714.g002
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adhesion [44]. To determine if PKCe is involved in NSCLC cell
invasiveness we assessed migration through Matrigel using a
Boyden chamber. Fig. 6A shows that PKCe-depleted A549 cells
essentially lost their ability to migrate through Matrigel (Fig. 6A).
On the other hand, knocking down PKCe did not affect the
adhesion of A549 cells to Matrigel (Fig. 6B). These findings
suggest that PKCe plays a critical role in the remodeling of the
matrix and prompted us to determine the expression of relevant
ECM proteases and protease inhibitors. As a first approach we
used a commercial qPCR array. Interestingly, mRNA levels of
ADAMTS1, MMP13, and MMP16 metalloproteinases were
down-regulated in PKCe-depleted A549 cells. PKCe depletion
also caused a marked induction in mRNA levels of overall the
protease inhibitors TIMP1 and TIMP2, suggesting an imbalance
in protease activity (Fig. 6C). As a complementary approach, we
also determined levels of metalloproteinases secreted to the
medium using an Antibody Array. Secretion of MMP3, MMP9,
MMP10, and MMP13 from PKCe-depleted cells to conditioned
medium was markedly reduced compared to control (Fig. 6D).
The reduction in MMP9 activity by PKCe depletion was
confirmed by zymography (Fig. S8). Thus, PKCe may affect
the synthesis and/or release of specific proteases from NSCLC
cells.
To establish the relevance of our findings in a metastasis model
in vivo, we examined the ability of A549 cells to form lung tumors
after i.v. inoculation into athymic nude mice. For these
experiments we generated stable PKCe-depleted A549 cell lines
(puromycin-selected) using two different shRNA lentiviruses. A
control cell line was generated by infection with a non-targeting
shRNA lentivirus (Fig. 7A). Mice were sacrificed 100 days after
inoculation. Notably, whereas control cells readily form macro-
scopic lung tumors in nude mice (7.561.5 tumor nodules/lung),
PKCe-depleted cells failed to form tumor nodules (0.460.2 and
1.560.5 tumor nodules/lung for e1 and e2, respectively) (Fig. 7B).
Quantification of the tumor areas in histological sections of the
lungs also showed remarkable differences between control and
PKCe-depleted A549 cells (Fig. 7C). Representative pictures of
lung tumors and H&E staining are depicted in Fig. 7D.
Finally, we carried out a survival experiment in athymic nude
mice. A549 cells subject to stable PKCe-depletion or control cells
were injected into the tail vein of athymic mice, and survival of the
Figure 3. Rac responses induced by serum are mediated by PKCe. A. NSCLC cells were serum starved for 24 h and then incubated with 10%
FBS (5 min). Rac-GTP levels determined using a pull-down assay. A representative experiment is shown and the induction of Rac, determined by
densitometry, is provided at the bottom of Western blot. Data are expressed as mean 6 S.D. (n=3). B and C. A549 cells were infected with AdVs for
either b2-chimaerin (b2-chn)( Panel C) or N17-Rac1 (Panel D) at the MOIs indicated in the figure. A LacZ AdV was used as control. Migration in
response to FBS was assayed using a Boyden chamber for 16 h. Left panels, representative micrographs. Right panels, quantification of 3 independent
experiments. Data are expressed mean 6 S.E.M. (n=3). **, p,0.01; ***, p,0.001. D. Rac activation by 10% FBS (2 min) in A549 cells subject to either
PKCe or control RNAi, as determined using a pull-down assay. A representative experiment is shown and the induction of Rac, determined by
densitometry, is provided at the bottom of each Western blot. Data are expressed as mean 6 S.D. (n=3). E. Migration of A549 and H358 cellssubject
to either PKCe or control RNAi in response to 10% FBS (16 h) using a Boyden chamber. Left panels, representative micrographs. Right panels,
quantitation of 3 independent experiments. Data are expressed mean 6 S.E.M. (n=3). **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0031714.g003
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whereas 100% of mice injected with control A549 cells died at
,200 days after inoculation, those injected with PKCe-depleted
cells have overall survival rates of 80% (PKCe shRNA #1) and
50% (PKCe shRNA #2) at 250 days. Altogether, these
experiments suggest an important role for PKCe in NSCLC cell
invasion and metastatic dissemination.
Discussion
Although the involvement of PKCs in carcinogenesis has been
recognized for decades, the specific roles of individual PKC
isoforms during specific stages of cancer progression remain only
partially understood, particularly in metastatic dissemination. This
is evident in lung cancer, where PKCs, mainly those isoforms
Figure 4. EGF-induced activation of Rac and Rac-mediated responses in A549 cells is mediated by PLC and PKCe. A. Effect of AG1478
(0.1–1 mM) and PRI-4 (0.1–1 mM) on the activation of Rac by 10% FBS (2 min). A representative experiment is shown. Values indicate the fold-
induction in Rac-GTP levels normalized to total Rac relative to levels at time=0, as determined by densitometry. Data are expressed as mean 6 S.D.
(n=3). B. Effect of EGFR depletion on the activation of Rac by 10% FBS (2 min).Values indicate the fold-induction in Rac-GTP levels normalized to total
Rac at time=0, as determined by densitometry. Data are expressed as mean 6 S.D. (n=3). C. Effect of AG1478 (1 mM) or EGFR RNAi on 10% FBS-
induced A549 cell migration using a Boyden chamber (16 h). Left panels, representative micrographs. Right panel, quantification of 3 independent
experiments. Data are expressed mean 6 S.E.M. (n=3). ***, p,0.001. D.A549 cells subject to either PKCe or control (CTRL) RNAi were serum starved
for 24 h and stimulated with EGF (100 ng/ml, 2 min). Rac activation was determined with a pull-down assay. Data are expressed as mean 6 S.D.
(n=3). E. Induction of ruffle formation by EGF (100 ng/ml, 15 min) in A549 cells subject to either PKCe or control (CTRL) RNAi. Left, representative
micrographs are shown (n=3). Right, quantification of cells bearing ruffles, expressed as mean 6 S.D. of 3 individual experiments. ***, p,0.001. F.
Effect of U73343 or U73122 (10 mM, 30 min) on Rac activation by either EGF (100 ng/ml) or PMA (100 nM, 2 min) in A549 cells. Values indicate the
fold-induction in Rac-GTP levels normalized to total Rac at time=0, as determined by densitometry. Data are expressed as mean 6 S.D. (n=3).
doi:10.1371/journal.pone.0031714.g004
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been poorly studied. Here we demonstrate that PKCe plays an
essential role in lung cancer cell motility and invasiveness. Our
studies identified PKCe as a key regulator of Rac1 activation in
response to stimuli in NSCLC cells. Notably, RNAi depletion or
pharmacological inhibition of PKCe impairs Rac1 activation as
well as Rac-dependent responses, including ruffle formation,
migration, and invasion. Rac1, a member of the Rho family of
small GTPases plays crucial roles in the reorganization of actin
cytoskeleton and motility, and inhibition of Rac1 or its
downstream effectors severely impairs cell migration and dissem-
ination of cancer cells [45]. Studies have shown that Rac is
required for migration of NSCLC cells [46], which we validated in
this study using a dominant-negative Rac mutant and by
expressing the Rac-GAP b2-chimaerin. Aberrant expression of
Rac exchange factors (Rac-GEFs) Ect2 and Vav1/2/3 has been
reported in lung cancer [47,48,49], suggestive of a crucial role for
the Rac signaling pathway in the progression of the disease.
Figure 5.The PKCe inhibitor eV1-2 impairs the formation of ruffles and migration in NSCLC cells. A. A549 or H358 cells were serum
starved for 24 h and migration in response to 10% FBS for 16 h determined using a Boyden chamber in the presence of either eV1-2 or control TAT
(1 mM). Left panels, representative micrographs. Right panels, quantification of migratory cells. Data are expressed as the mean 6 S.D. of 3 individual
experiments. ***, p,0.001. B. Induction of ruffle formation by 10% FBS (30 min) in A549 cells in the presence of increasing concentrations of eV1-2.
Left, representative micrographs. Right, quantification of cells bearing ruffles expressed as mean 6 S.D. of 3 individual experiments.***, p,0.001. C.
Effect of eV1-2 on Rac activation by 2% FBS (2 min) (left panel) or EGF (10 ng/ml, 2 min) (right panel). The concentration of eV1-2 in the EGF
experiments was 1 mM. Representative experiments are shown. Values indicate the fold-induction in Rac-GTP levels normalized to total Rac relative to
levels at time=0, as determined by densitometry. Data are expressed as mean 6 S.D. (n=3).**, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0031714.g005
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31714Figure 6. PKCe modulates invasion and ECM-genes in A549 cells. A. A549 cells were transfected with RNAi for either PKCe (e1 and e2) or
control (CTRL) and 2 days later serum-starved for additional 24 h. Cells were then seeded in Boyden chambers with Matrigel-coated membranes.
Invasion was quantified 24 h later. Left, representative micrographs. Right, quantification of invasive cells. Data are represented as mean 6 S.E.M.
(n=3). ***, p,0.001. B. Adhesion to Matrigel-coated plates was determined 24 h after seeding. Data are represented as mean 6 S.E.M. (n=3). C.
Analysis of proteases and inhibitors of proteases by qPCR in control or PKCe-depleted cells. Results are expressed as mean 6 S.E.M. (n=4). D.
Detection of ECM proteases secreted to conditioned medium (CM) from control or PKCe-depleted A549 cells. Quantification of MMP levels by
densitometry is represented as mean 6 S.E.M. (n=3). **, p,0.01; ***, p,0.001. N.D., not-determined.
doi:10.1371/journal.pone.0031714.g006
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connection between PKC isozymes and the invasive phenotype.
Several reports have directly or indirectly suggested a link between
PKCe and invasiveness, and PKCe was found to be highly
overexpressed in lung cancer as well as in other epithelial cancers
[14], prompting us to reason that this PKC may be highly relevant
for NSCLC metastatic dissemination. Indeed, early studies showed
that NIH 3T3 fibroblasts overexpressing PKCe acquire a
polarized morphology and form invadopodial-like structures
[20], and that PKCe signals downstream of b1-integrin to
modulate cell spreading [14]. PKCe regulates motility and
invasion in models of breast as well as head and neck cancer, at
least partially through RhoA and RhoC GTPases [19,50].
Moreover, skin transgenic overexpression of PKCe in mice leads
to the development of metastatic squamous carcinomas [51]. A
link between PKCe and Rac has been reported in lung endothelial
cells downstream of the sphingosine-1-phosphate receptor [52].
Experiments presented in our study show that there are major
changes in the expression of proteases related to invasiveness upon
depletion of PKCe from NSCLC cells. A number of MMPs
(ADAMTS1, MMP1, MMP2, MMP10, MMP13, MMP14 and
MMP16) are down-regulated at the mRNA level, whereas the
Figure 7. PKCe plays a role in invasion and metastatic dissemination of NSCLC cells. A549 cells were subject to stable PKCe depletion
using two different shRNA lentiviruses (e1 and e2) or control cells (CTRL, non-target shRNA lentivirus) and selected with puromycin. Cells were
inoculated i.v. into athymic mice. A. Levels of PKCe depletion achieved in stable cells lines. A representative Western blot is shown. B. Incidence of
metastasis per lung in mice sacrificed 100 days post-inoculation of cells. *, p,0.05; **,p,0.01. C. Area of tumors as determined in microscopic images.
**, p,0.01. D. Representative images of lungs from mice inoculated with PKCe-depleted or control cells. Arrows, metastatic foci in whole-fixed lungs
(top panels) or in lungs stained with hematoxilin and eosin (H&E) (bottom panels). E. Overall survival of mice inoculated with PKCe-depleted or control
A549 cells.
doi:10.1371/journal.pone.0031714.g007
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knockdown NSCLC cells. Furthermore, the overall secretion of
several MMPs from NSCLC cells was markedly reduced by PKCe
RNAi. Although the requirement for Rac in the regulation of
protease/protease inhibitors in NSCLC cells remains to be
determined, recent studies in different cellular models identified
Rac signaling as a requirement for the secretion of MMP9, MMP2
and MMP1 [53,54,55]. Moreover, in lung cancer cells Rac
mediates PKCi-induced secretion of MMP10 [56], suggesting
common downstream targets for PKC isozymes controlling
invasion. Thus, it is conceivable that PKCe overexpression signals
via Rac to impact on the expression of multiple proteases, leading
ultimately to enhanced invasiveness of lung cancer cells.
Our results identified PKCe as an essential mediator of Rac1
activation downstream of the EGFR, a receptor that couples to
PLCc to generate DAG in response to its activation [39]. In
PKCe-depleted NSCLC cells EGF fails to activate Rac or Rac-
dependent responses, including ruffle formation and motility.
Pharmacological inhibition of PLC impairs Rac activation by
EGF, arguing that DAG-mediated recruitment of PKCe to the
plasma membrane plays a crucial role in the activation of the Rac
signaling pathway. How PKCe controls Rac activation down-
stream of EGFR (or eventually other tyrosine-kinase receptors)
remains unexplored, hence identifying such mechanisms merits
further investigation. One attractive mechanism may involve the
activation of exchange factors for Rac (Rac-GEFs) through
phosphorylation. There are at least 25 Rac-GEFs in the genome,
and their relative expression in lung cancer has not been fully
established. Using a Rac-GEF qPCR array we recently found that
NSCLC cell lines express high levels of Vav1/2, Ect2, DEPC2 and
DEPC1 compared to normal cells (M.C.C. and M.G.K.,
unpublished studies). Elegant studies by Fields and coworkers
demonstrated that Ect2 is required for the oncogenic activity of
PLCi, a member of the atypical PKC family. Ect2 is overexpressed
in lung cancer and is an essential component of the PKCi-Par6
complex that controls cell polarity. RNAi-mediated knockdown of
Ect2 in A549 cells inhibits Rac1 activity as well as it impairs
growth, tumorigenicity and invasion of NSCLC cells [48].
However, upon RNAi depletion of Ect2 from A549 cells we
could not find any significant changes in Rac1 activation induced
by EGF (C.L.H. and M.G.K., unpublished studies). These results
argue for major differences in the regulation of Rac signaling by
DAG-responsive and DAG-unresponsive PKCs. Vav isoforms,
Rho/Rac-GEF overexpressed in nearly half of human primary
lung tumors [49], are candidate PKCe effectors. Vav1 activation is
regulated by tyrosine phosphorylation, and it may be also
regulated by serine/threonine kinases [57]. Very recently, Vav1
was found to be associated with PKC h, a member of the nPKC
family closely related to PKCe [58]. Other small GTPase GEFs
regulated by serine/threonines kinases include STEF, b1-Pix, and
GEF-H1 [59,60,61]. Moreover, phorbol esters can activate Rho
GTPases through mechanisms that involve Rho-GEF activation
[62,63]. Conceivably, similar mechanisms may take place on Rac-
GEFs via specific phosphorylation by PKCe. PKCe may also
modulate Rac-GAPs that control the rate of GTP hydrolysis from
the GTPase. For example, phorbol esters stimulate the phosphor-
ylation of the Rho-GAP DLC1, leading to its relocalization and
suppression of GAP activity [64]. Very recently, our laboratory
identified a PKC-mediated phosphorylation mechanism that
modulates the association of the Rac-GAP b2-chimaerin to the
plasma membrane [6]. The identification of those substrates of
PKCe implicated in the regulation of the Rac signaling pathway
will certainly provide important insights into the mechanisms of
lung cancer metastasis.
Finally, our studies may have significant therapeutic implica-
tions. Several modulators of PKC activity have been clinically
tested for different types of malignancies with variable degrees of
success [32,65,66]. Despite the established oncogenic and
invasive activity of PKCe, to our knowledge PKCe inhibitors
have not been tested as anti-cancer agents. This may be largely
due to the failure to develop selective inhibitors directed against
the ATP-binding site of PKCe, a shortcoming also observed for
several other members of the PKC family. Nonetheless, here we
found that the specific PKCe translocator inhibitor eV1-2 impairs
Rac1 activation and migration in a similar manner as observed
upon delivery of PKCe RNAi duplexes. In preliminary studies we
found that systemic delivery of eV1-2 fused to the permeable
peptide TAT inhibits NSCLC xenograft growth in nude mice
(M.C.C., C.L.H., and M.G.K., unpublished observations). Our
studies may establish a framework for designing PKCe inhibitors
as anti-cancer agents, particularly for those malignancies such as
lung cancer for which there are currently limited therapeutic
options available.
Supporting Information
Figure S1 PKC activation induces lamelipodia and
ruffles in NSCLC cells. Cells were serum starved for 24 h,
pretreated with the pan-PKC inhibitor GF109203X (5 mM,
30 min) and stimulated with PMA (100 nM, 30 min) in the
presence of the inhibitor. After washing, cells were fixed and
stained with rhodamine-phalloidin. A representative micrograph is
shown (n=3).
(TIF)
Figure S2 PKC activation accelerates wound closure in
NSCLC cells. Cells were serum starved for 24 h, pretreated with
the pan-PKC inhibitor GF109203X (5 mM, 30 min) and stimu-
lated with PMA (100 nM, 30 min). After washing, monolayers
were scraped and the closure of the wound was followed for 9 h
(A549) or 20 h (H358 and H1299). A representative micrograph is
shown.
(TIF)
Figure S3 Human NSCLC cell lines express high levels
of PKCe compared to non-tumorigenic immortalized
bronchioepithelial cells (HBE). Expression was determined
by Western blot. Similar results were observed in 3 independent
experiments.
(TIF)
Figure S4 PKCe mediates Rac activation and Rac-
mediated responses induced by PMA in H322 cells.
H322 cells were transfected with either PKCe RNAi (e1o re2)
or control (CTRL) RNAi and serum starved for 24 h. A) Cells
were treated with PMA (100 nM, 30 min), fixed, and stained with
phalloidin-rhodamine. Representative micrographs are shown
(n=3). B) Quantification of H322 cells bearing ruffles, expressed
as mean 6 S.D. of 3 individual experiments. **, p,0.01;
***, p,0.001. C) Closure of wounds in response to PMA
(100 nM, 30 min) was recorded at 20 h. Experiments were carried
out in triplicate plates. A representative micrograph is shown
(n=3).
(TIF)
Figure S5 Cell viability with treatments used for
Boyden chamber experiments. A) Left panel, A549 cells were
serum starved for 24 h, trypsinized and plated for either MTT
assays in the presence of the indicated inhibitors (16 h). Data are
expressed as mean 6 S.D. (n=6). Right panel, PKCe depletion
achieved by transient transfection of siRNA. B) Cells were seeded
PKCe Activation of Rac1 in Lung Cancer
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31714in Boyden chambers in the presence of vehicle or GF109203X
(5 mM). FBS (10%) was added to the lower compartment.
Migratory cells were determined 16 h later. Left panel, represen-
tative experiments. Right panel, quantification of migratory cells.
Data are expressed as mean 6 S.E.M. (n=3). ***, p,0.001.
(TIF)
Figure S6 PKCe overexpression enhances wound clo-
sure induced by serum in NSCLC cells. Cells were infected
with adenovirus (AdV) coding the indicated proteins, serum
starved for 24 h and assayed for migration in response to serum
(FBS) with either wound assays or Boyden chambers. Cells were
infected with a control (LacZ) or PKC AdVs at multiplicities of
infection=100 pfu/cell. A) Expression of PKC isozymes at the
day of the experiment. B) Representative micrographs for a wound
assay in A549 infected with LacZAdV or PKCe AdV. C)
Quantification of wound closure induced by 10% FBS for H358
or A549 cells infected with LacZ, PKCa, PKCd or PKCe AdVs.
Data are expressed as mean 6 S.E.M. (n=3). *, p,0.05;
**, p,0.01; ***, p,0.001.
(TIF)
Figure S7 eV1-2 concentration-response in migration
assays. H358 cells were seeded in Boyden chambers in the
presence of TAT 10 mMo reV1-2 (0.1–10 mM). FBS (10%) was
added to the lower compartment. Migratory cells were measured
at 16 h. Left panel, representative experiments. Right panel,
quantification of migratory cells. Data are expressed as mean 6
S.E.M. (n=3). ***, p,0.001.
(TIF)
Figure S8 Detection of ECM-proteases secreted to
conditioned media (CM) either from control or PKCe-
depleted A549 cells. A549 cells transfected with either PKCe
RNAi or control duplexes, and CM was collected as described in
Experimental Procedures. A) ECM-proteases were detected in
CM from control (CTRL-CM) or PKCe-depleted cells (PKCe-CM)
using a protein array detection system from RayBiotech. IC,
internal positive control. B) MMP9 activity was assayed by
zymography. Two additional experiments gave similar results.
(TIF)
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